Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity

Cellular Oncology

Volumn 35, Issue 6, 2012, Pages 423-434

  Wei, Li ^a,b   Mei, Fan Dong ^a   Ming, Yang ^a   Zan, Shi Rui ^c   Yan, Yan ^a   Linlin, Jiang ^a   Cihui, Yan ^a   Shuangjing, Li ^a   Min, Wang ^a   Jianxiang, Wang ^a   Sheng, Xiong Dong ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

AntiCD19; AntiCD3; Bispecific antibody; Cancer immunotherapy; Diabody; Disulphide crosslinks

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD19 ANTIBODY; CD19 ANTIBODY CD3 ANTIBODY; CD19 ANTIGEN; CD3 ANTIBODY; CD3 ANTIGEN; CYSTEINE; DISULFIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG RECEPTOR BINDING; ESCHERICHIA COLI; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTIBODY AFFINITY; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; GENETIC ENGINEERING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NUDE MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIGENS, CD19; ANTIGENS, CD3; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879245589     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0101-9     Document Type: Article

References (33)

1. C. Andreadis, S.J. Schuster, E.A. Chong, J. Svoboda, S.M. Luger, D.L. Porter et al., Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant. 36, 955-961 (2005)
2. B. Reismüller, A. Attarbaschi, C. Peters, M.N. Dworzak, U. Pötschger, C. Urban et al., Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br. J. Haematol. 144, 559-570 (2009)
3. P. Tsirigotis, T. Economopoulos, Monoclonal antibodies in the treatment of lymphoid malignancies. J. Steroid Biochem. Mol. Biol. 108, 267-271 (2008)
4. E. Oflazoglu, L.P. Audoly, Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MABS. 2, 14-19 (2010)
5. J.O. Richards, S. Karki, G.A. Lazar, H. Chen, W. Dang, J.R. Desjarlais, Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517-2527 (2008)
6. Y.H. Qu, Y. Li, Y.F. Wu, J.P. Fang, S.L. Huang, Y. Huang et al., Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18, 1269-1274 (2010)
7. M. Peipp, T. Valerius, Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. 30, 507-511 (2002)
8. P.A. Baeuerle, P. Kufer, R. Lutterbüse, Bispecific antibodies for polyclonal T-cell engagement. Curr. Opin. Mol. Ther. 5, 413-419 (2003)
9. K. Brischwein, L. Parr, S. Pflanz, J. Volkland, J. Lumsden, M. Klinger et al., Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798-807 (2007)
10. A. Löffler, P. Kufer, R. Lutterbüse, F. Zettl, P.T. Daniel, J.M. Schwenkenbecher et al., A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphomadirected cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098-2103 (2000)
11. Y. Reiter, U. Brinkmann, S.H. Jung, B. Lee, P.G. Kasprzyk, C.R. King et al., Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269, 18327-18331 (1994)
12. R.F. Graziano, P. Guptill, Chemical production of bispecific antibodies. Methods Mol. Biol. 283, 71-85 (2004)
13. Y. Reiter, R.J. Kreitman, U. Brinkmann, I. Pastan, Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer 58, 142-149 (1994)
14. Y. Reiter, L.H. Pai, U. Brinkmann, Q.C. Wang, I. Pastan, Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54, 2714-2718 (1994)
15. J. Liu, M. Yang, J. Wang, Y. Xu, Y. Wang, X. Shao et al., Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli. Cancer Immunol. Immunother. 58, 1761-1769 (2009)
16. D.C. Shen, X.F. Yang, A high affinity CD3 monoclonal antibody HIT3a. Acta Acad. Med. Sin. 15, 157-162 (1993)
17. S. Chen, Q. Rao, J.X. Wang, M. Wang, Construction and expression of single chain variable fragments (ScFv) against human CD19 antigen. Sheng Wu Gong Cheng Xue Bao. 21, 686-691 (2005)
18. Z. Zhu, P. Rockwell, D. Lu, H. Kotanides, B. Pytowski, D.J. Hicklin et al., Inhibition of vascular endothelial growth factorinduced receptor activation with anti-kinase insert domaincontaining receptor single-chain antibodies from a phage display library. Cancer Res. 58, 3209-3214 (1998)
19. B. Schlereth, C. Quadt, T. Dreier, P. Kufer, G. Lorenczewski, N. Prang et al., T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55, 503-514 (2006)
20. Y. Xu, D. Xiong, C. Yang, Z. Lai, H. Liu, X. He et al., The mutation of anti-CD3 antibody (HIT3a) gene and its expression. Zhonghua Xue Ye Xue Za Zhi 22, 252-255 (2001) [In Chinese.]
21. B.D. Choi, M. Cai, D.D. Bigner, A.I. Mehta, C.T. Kuan, J.H. Sampson, Bispecific antibodies engage T cells for antitumor immunotherapy. Expert. Opin. Biol. Ther. 11, 843-853 (2011)
22. P. Holliger, T. Prospero, G. Winter, "Diabodies": Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 90, 6444-6448 (2003)
23. Z. Zhu, G. Zapata, M.R. Shalaby, B. Snedecor, H. Chen, P. Carter, High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/Technology 14, 192-196 (1996)
24. P. Carter, J. Ridgway, Z. Zhu, Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4, 463-470 (1995)
25. U. Bfinkmann, I. Pastan, Recombinant immunotoxins: From basic research to cancer therapy. Methods 8, 143-156 (1995)
26. Y. Reiter, I. Pastan, Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: Disulfidestabilized Fv immunotoxins. Clin. Cancer Res. 2, 245-252 (1996)
27. Y. Reiter, U. Brinkmann, K. Webber, S.-H. Jung, B.K. Lee, I. Pastan, Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfidestabilized Fv. Protein Eng. 7, 697-704 (1994)
28. G.A. Leget, M.S. Czuczman, Use of rituximab, the new FDAapproved antibody. Curr. Opin. Oncol. 10, 548-551 (2008)
29. R. Vereecque, A. Saudemont, B. Quesnel, Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 18, 1223-1230 (2004)
30. M.M. Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J]. Clin. Ther. 21, 309-318 (2009)
31. R.E. Jimenez, M.M. Zalupski, J.J. Frank, W. Du, J.R. Ryan, D.R. Lucas, Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86(6), 976-981 (2008)
32. V.V. Rao, D.C. Anthony, D. Piwnica-Worms, Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J. Histochem. Cytochem. 43, 1187-1192 (2009)
33. M. Yang, D.M. Fan, Y.D. Gao, Y. Zhou, Q. Ji, X.F. Shao, J.H. Wang, Y.F. Xu, D.S. Xiong, C.Z. Yang, The influence of Ara-C on anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells. Zhonghua Xue Ye Xue Za Zhi 30, 812-815 (2009) [In Chinese.]